Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign up
Research Summary

Lixisenatide shows no significant effect on arterial stiffness in diabetes.

Moderate confidence
Low bias
Last updated July 8, 2026

Key Takeaway:

The study evaluated the impact of lixisenatide on aortic pulse wave velocity in patients with CKD and type 2 diabetes, finding no significant changes.

Study at a Glance

What was studied

24 weeks of treatment with lixisenatide compared to placebo in adults with type 2 diabetes and CKD.

Participants

Young Adult (19–39), Middle Aged (40-64)

Male, Female

with T2 Diabetes

Intervention

Lixisenatide

Outcomes

Aortic pulse wave velocity, Albuminuria, HbA1c

Funding

Non-Industry Sponsored

Save this study and add notes to your research library.

Main Effects

Ao-PWV did not change significantly from baseline after 24 weeks, p = 0.38.

No significant changes were observed in albuminuria, p = 0.09.

HbA1c decreased with lixisenatide compared to placebo.

Evidence Summary

InterventionOutcomeMeasured ChangeStudy Effect
Medications
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
(Medications)
Clinical Outcomes
Albuminuria
(Clinical Outcomes)
No Change
Unclear
Medications
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
(Medications)
Clinical Outcomes
Change in aortic pulse wave velocity from baseline to week 24
(Clinical Outcomes)
No Change
Unclear
Medications
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
(Medications)
Glycemic Control
HbA1c
(Glycemic Control)
Decrease
Unclear

Unlock Full Evidence Analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

evidence suggest

Evidence Suggest

  • Ao-PWV remained stable at 9.65 m/s with lixisenatide versus 9.96 m/s with placebo.
  • Albuminuria showed no significant change, p = 0.09.
  • HbA1c levels decreased with lixisenatide, indicating improved blood sugar control.
who this applies

Who this applies to

  • Adults with chronic kidney disease (CKD).
  • Individuals diagnosed with type 2 diabetes.
keep in mind

Keep in Mind

  • Results may not apply to populations outside of those studied.
  • The study focused on short-term effects; long-term implications are unknown.
  • Further research is needed to explore other potential benefits of lixisenatide.
between the lines

Between the Lines

  • The study may have limited generalizability due to specific population characteristics.
  • Sample size and duration may not have been sufficient to detect subtle changes.
  • The study did not assess long-term effects beyond 24 weeks.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Journal Reference

Nikolaos F, Panagiotis P, Dimitra S, et al. In people with CKD and type 2 diabetes the use of short-acting GLP-1 RA lixisenatide did not significantly influence Ao-PWV. Diabetes, Obesity & Metabolism. 2026;28(4):2953-2961. doi:10.1111/dom.70481

View DOIView on PubMedView on PMC

Connected Evidence

Discover how this study fits into the broader diabetes evidence landscape.

This study contributes to evidence on Insulin Therapies and HbA1c.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention–outcome relationships.

Questions this evidence helps answer

Key clinical and research questions this study contributes to.

Does insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) improve HbA1c?

Based on connected evidence for Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and HbA1c.

How connections are generated

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.